Skip to content

Public FDA record

Z-0774-2018: 14-442000S Antegrade Femoral Nail Instrument Kit, orthopedic instrument

Recall record Z-0774-2018 for Zimmer Biomet, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0774-2018
Company in FDA record
Zimmer Biomet, Inc.
FDA record creation date
Feb 27, 2018
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Fracture of the bolt connecting the insertion guide to the intramedullary nail during insertion of the femoral nail.

Source facts

Action
On September 13, 2017 an URGENT MEDICAL DEVICE RECALL REMOVAL was issued to customers requesting that they review inventory and quarantine affected product, which will be immediately returned to recalling firm. Also to notify any customers who may have received product. Questions or concerns can be directed to Customer Service at 574-371-3071
Initiated
2017-09-13
Root cause
Device Design
Terminated
2020-04-21
Distribution
Distribution includes US Nationwide.
Recall number
Z-0774-2018
Recall status
Terminated
CDRH record ID
161442
FDA record created
2018-02-27
Recall event number
79146

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗